Top Page
CStone Pharmaceuticals
(2616)
CStone Pharmaceuticals (2616) vs. iShares MSCI Hong Kong ETF (EWH)
CStone Pharmaceuticals Business Overview & Revenue Model
CStone Pharmaceuticals Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 407.20M | 463.84M | 481.36M | 243.72M | 1.04B | Gross Profit |
| 240.15M | 304.30M | 278.38M | 136.89M | 797.41M | EBIT |
| -91.69M | -534.61M | -832.27M | -1.85B | -1.22B | EBITDA |
| -76.43M | -297.23M | -849.66M | -1.90B | -1.20B | Net Income Common Stockholders |
| -91.21M | -367.23M | -964.61M | -1.99B | -1.22B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 672.94M | 1.05B | 1.04B | 1.73B | 3.39B | Total Assets |
| 1.39B | 1.66B | 1.64B | 2.27B | 3.76B | Total Debt |
| 355.97M | 363.45M | 286.29M | 174.20M | 83.86M | Net Debt |
| -31.96M | -633.22M | -272.39M | -568.53M | -2.94B | Total Liabilities |
| 1.03B | 1.21B | 1.19B | 1.06B | 808.29M | Stockholders Equity |
| 363.87M | 456.83M | 449.33M | 1.21B | 2.95B |
| Cash Flow | Free Cash Flow | |||
| 0.00 | -653.89M | -714.29M | -1.63B | -579.52M | Operating Cash Flow |
| 0.00 | -588.84M | -612.47M | -1.48B | -508.07M | Investing Cash Flow |
| 0.00 | 619.61M | 365.12M | -826.55M | 1.18B | Financing Cash Flow |
| 0.00 | 388.36M | 28.47M | 92.30M | 1.39B |
CStone Pharmaceuticals Technical Analysis
CStone Pharmaceuticals Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | HK$238.00B | 10.13 | 17.31% | 3.87% | 10.29% | 11.02% | |
55 Neutral | HK$82.62B | ― | -8.98% | ― | -54.66% | -123.11% | |
54 Neutral | HK$33.71B | ― | -56.68% | ― | 52.25% | 11.46% | |
53 Neutral | $5.22B | 3.33 | -44.36% | 7.55% | 16.78% | -0.12% | |
42 Neutral | HK$5.29B | ― | -22.23% | ― | -14.17% | 76.00% | |
| $12.49B | 28.61 | 8.17% | ― | ― | ― | ||
52 Neutral | HK$32.88B | ― | -19.78% | ― | 25.96% | 39.58% |
CStone Pharmaceuticals Corporate Events
CStone Pharmaceuticals announced the grant of 6,757,200 Restricted Share Units (RSUs) and 15,766,800 Share Options to 95 grantees, including a director and employees, under its Post-IPO RSU Scheme and ESOP. This strategic move aims to incentivize and retain key personnel, potentially enhancing the company’s operational efficiency and competitive positioning in the biopharmaceutical industry.
CStone Pharmaceuticals has successfully completed the placing of 80 million new shares under a general mandate, raising approximately HK$232.29 million. This strategic move, which involved placing shares to professional and institutional investors, represents about 5.86% of the company’s enlarged share capital and is intended to support the company’s operational and strategic initiatives.
CStone Pharmaceuticals announced that its CEO and executive director, Dr. Jianxin Yang, has increased his shareholding in the company by purchasing an additional 560,000 shares, bringing his total to 10,359,000 shares. This move signifies Dr. Yang’s confidence in the company’s future prospects and his commitment to its growth and stability in a challenging market environment.
CStone Pharmaceuticals has announced a placement of 80 million new shares at a price of HK$2.933 per share, representing a discount to recent trading prices. This move is expected to raise gross proceeds of HK$234.64 million, which will contribute to the company’s financial resources. The placement is contingent upon approval from the Stock Exchange’s listing committee and other conditions, and it will increase the company’s issued share capital by approximately 5.86%. Shareholders and potential investors are advised to exercise caution as the completion of the placement is not guaranteed.
CStone Pharmaceuticals announced its annual results for the year ended December 31, 2024, reporting a total revenue of RMB407.2 million, which reflects a decrease of 12.2% from the previous year. Despite the decline in revenue, the company significantly reduced its loss for the year to RMB91.2 million, a 75.2% decrease from 2023, primarily due to a substantial reduction in operating expenses, including research and development, administrative, and selling and marketing expenses.
CStone Pharmaceuticals announced its participation in the AACR 2025 Annual Meeting, where it will present five preclinical studies on innovative cancer treatment candidates. These include the trispecific antibody CS2009 and several ADCs developed from CStone’s proprietary platform. The showcased candidates demonstrate potential for enhanced anti-tumor efficacy and safety, positioning CStone as a leader in next-generation cancer therapies. This announcement highlights CStone’s commitment to advancing cancer treatment and its strategic focus on leveraging its proprietary technologies to address unmet medical needs in oncology.
CStone Pharmaceuticals has submitted a Type II variation application to the European Medicines Agency for sugemalimab, seeking approval for its use in treating unresectable stage III non-small cell lung cancer (NSCLC) post-chemoradiotherapy. This submission follows its earlier approval for metastatic NSCLC in Europe. If approved, sugemalimab could become a key immunotherapy for lung cancer, addressing a critical unmet need in stage III NSCLC. The application is backed by positive results from the GEMSTONE-301 Phase III trial, which demonstrated significant improvements in progression-free and overall survival rates, along with a favorable safety profile.
CStone Pharmaceuticals has announced a board meeting scheduled for March 27, 2025, to discuss and approve the company’s annual results for the year ending December 31, 2024. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and stakeholder interests.
CStone Pharmaceuticals announced the submission of a Phase Ib clinical trial application in Australia for CS5001, a ROR1-targeting antibody-drug conjugate, in combination with first-line standard-of-care for diffuse large B-cell lymphoma (DLBCL). This trial aims to expand the therapeutic potential of CS5001 across all DLBCL stages and solid tumors, potentially reshaping the standard-of-care landscape. The global multi-center trial is actively enrolling patients, with promising data indicating significant clinical benefits for DLBCL patients and potential expansion into a Phase II study. CS5001 has shown encouraging safety and anti-tumor activity in preclinical models, with a favorable safety profile and potential for precision treatment in both hematologic and solid tumors.
CStone Pharmaceuticals has announced the successful dosing of the first patient in a global multicenter Phase I clinical trial for its innovative trispecific antibody, CS2009. This trial aims to evaluate CS2009’s potential in treating various advanced solid tumors, including non-small cell lung cancer and gastric adenocarcinoma. CS2009, which targets PD-1, VEGFA, and CTLA-4, has shown superior anti-tumor activity in preclinical studies compared to existing therapies. The trial’s initiation marks a significant milestone for CStone, potentially positioning CS2009 as a next-generation immunotherapy product with enhanced efficacy and safety for patients with low or negative PD-L1 expression.
CStone Pharmaceuticals has announced the publication of the GEMSTONE-303 study results in the Journal of the American Medical Association, highlighting the efficacy of sugemalimab (Cejemly®) in combination with chemotherapy for treating gastric or gastroesophageal junction adenocarcinoma. The study demonstrated significant improvements in overall survival and progression-free survival for patients with PD-L1 CPS ≥5, positioning sugemalimab as a potential new standard first-line treatment. The results support CStone’s ongoing efforts to expand regulatory approvals and strengthen its position in the oncology market.
CStone Pharmaceuticals announced that its product, sugemalimab (Cejemly®), has been included in the European Society for Medical Oncology (ESMO) guidelines as a recommended first-line combination therapy for both squamous and non-squamous NSCLC. This significant inclusion underscores sugemalimab’s clinical benefits, as evidenced by the Phase III GEMSTONE-302 trial, and supports CStone’s global market expansion efforts. The company is actively pursuing strategic partnerships to further extend market access in Western Europe, Southeast Asia, and Canada.